[ET Net News Agency, 15 October 2021] Hansoh Pharmaceutical Group Company Limited
(03692) said the company has entered into an exclusive licence and collaboration agreement
with Silence Therapeutics plc (Silence Therapeutics).
The company and Silence Therapeutics will collaborate to develop siRNAs (short
interfering RNAs) for three targets leveraging Silence Therapeutics' proprietary mRNAi GOL
platform. For the first two targets, the company will have the exclusive option to licence
rights in China (including Hong Kong, Macau and Taiwan) (the territory) following the
completion of phase 1 studies and Silence Therapeutics will retain exclusive rights in
rest of the world other than the territory. Silence Therapeutics will be responsible for
all activities up to option exercise and will retain responsibility for development
outside the territory post phase 1 studies for the first two targets. For the third
target, the company will have the exclusive option to licence global rights at the point
of Investigational New Drug (IND) filing. The company will be responsible for all
development activities post option exercise for the third target. (RC)